4.7 Article

Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Pharmacology & Pharmacy

The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders

Beltran Alvarez-Perez et al.

Summary: Dual enkephalinase inhibitors (DENKIs) provide an innovative strategy to activate opioid receptors and treat opioid use disorders by protecting endogenous opioid peptides. They have the potential to be a safe and effective treatment for acute opioid withdrawal and a promising alternative to opioid substitution therapy with minimized side effects.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Neurosciences

Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation

Bing Hu et al.

Summary: The study confirmed the inhibitory effect of VNS in the treatment of migraine and demonstrated that this effect could be prevented by a broad-spectrum opioid receptor antagonist and a highly selective DOR antagonist. The results further supported the important role of DOR in headache mechanisms and provided evidence of the involvement of opioidergic mechanisms in the therapeutic action of VNS.

NEUROPHARMACOLOGY (2021)

Article Anesthesiology

Delta opioid receptor regulation of calcitonin gene-related peptide dynamics in the trigeminal complex

Laura S. Moye et al.

Summary: DOP agonists show promise in alleviating chronic migraine-associated pain by modulating CGRP release and blocking CGRPR signaling. Coexpression of DOP with CGRP and its receptor components was observed in the trigeminal system, suggesting a potential mechanism of action for migraine treatment.
Review Medicine, General & Internal

Migraine: integrated approaches to clinical management and emerging treatments

Messoud Ashina et al.

Summary: Migraine is a highly disabling neurological disorder affecting over 1 billion people worldwide. Treatment options include pharmacological and non-pharmacological therapies. Building a personalized treatment plan and exploring emerging mechanism-based treatments are crucial for effective management.

LANCET (2021)

Article Multidisciplinary Sciences

Biased signaling by endogenous opioid peptides

Ivone Gomes et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Review Physiology

PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING

Peter J. Goadsby et al.

PHYSIOLOGICAL REVIEWS (2017)

Article Multidisciplinary Sciences

Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7

Michael S. Minett et al.

NATURE COMMUNICATIONS (2015)

Article Chemistry, Medicinal

New Orally Active Dual Enkephalinase Inhibitors (DENKIs) for Central and Peripheral Pain Treatment

Herve Poras et al.

JOURNAL OF MEDICINAL CHEMISTRY (2014)

Article Anesthesiology

Characterization of a novel model of chronic migraine

Amynah A. Pradhan et al.

Review Clinical Neurology

Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology

Carolyn Bernstein et al.

JOURNAL OF CLINICAL NEUROLOGY (2012)

Review Biotechnology & Applied Microbiology

Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain

Bernard P. Roques et al.

NATURE REVIEWS DRUG DISCOVERY (2012)